TIDMPRTC
PureTech Health PLC
23 May 2023
23 May 2023
PureTech Health plc
PureTech Founded Entity Sonde Health Announces Respiratory
Responsive Vocal Biomarker Tool Differentiates Patients with
Respiratory Conditions from Healthy Individuals
Study published in JMIR suggests that RRVB tool could help to
pre-screen acute respiratory infections, including asymptomatic
COVID-19
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company, noted today
that its Founded Entity, Sonde Health , a health technology company
committed to bringing accessible health monitoring to everyone, has
revealed new research that demonstrates the ability of its
respiratory responsive vocal biomarker (RRVB) machine learning
model to differentiate patients with COVID-19 from healthy
individuals with about 70% accuracy.
The RRVB tool had already shown strong performance in
differentiating patients with asthma, chronic obstructive pulmonary
disease (COPD), interstitial lung disease, and cough from healthy
individuals. In the new study, conducted in collaboration with
Montefiore Health System, Brigham and Women's Hospital, UC San
Diego Health System, and Deenanath Mangeshkar Hospital in Pune,
India, the model achieved 73% sensitivity and 63% specificity for
the entire COVID-19 population (97 patients), and it detected 66%
of asymptomatic COVID-19 subjects (46 patients) using only a
six-second recording of an "ahh" vowel sound on patient
smartphones. These findings suggest the tool could help uncover
respiratory conditions before symptoms arise.
The peer-reviewed study , which was published in the Journal of
Medical Internet Research (JMIR), suggests the RRVB tool could
serve as a pre-screening tool for acute respiratory infection and
pave the way for the development of voice-based tools for future
disease detection and monitoring applications.
The full text of the announcement from Sonde is as follows:
Sonde Health's Respiratory Responsive Vocal Biomarker Tool
Differentiates Patients with Respiratory Conditions from Healthy
Individuals
Study published in JMIR suggests that RRVB tool could help to
pre-screen acute respiratory infections, including asymptomatic
COVID-19
BOSTON, MA - May 23, 2023 - Sonde Health , a health technology
company committed to bringing accessible health monitoring to
everyone, has revealed new research that demonstrates the ability
of its respiratory responsive vocal biomarker (RRVB) machine
learning model to differentiate patients with COVID-19 from healthy
individuals with about 70% accuracy.
The peer-reviewed study , which was published in the Journal of
Medical Internet Research (JMIR), suggests the RRVB tool could
serve as a pre-screening tool for acute respiratory infection and
pave the way for the development of voice-based tools for future
disease detection and monitoring applications.
The RRVB tool had already shown strong performance in
differentiating patients with asthma, chronic obstructive pulmonary
disease (COPD), interstitial lung disease, and cough from healthy
individuals. In the new study, conducted in collaboration with
Montefiore Health System, Brigham and Women's Hospital, UC San
Diego Health System, and Deenanath Mangeshkar Hospital in Pune,
India, the model achieved 73% sensitivity and 63% specificity for
the entire COVID-19 population (97 patients), and it detected 66%
of asymptomatic COVID-19 subjects (46 patients) using only a
six-second recording of an "ahh" vowel sound on patient
smartphones. These findings suggest the tool could help uncover
respiratory conditions before symptoms arise.
"We have shown that the same technology originally developed for
asthma and COPD can be applied to pre-screen for COVID-19 with
meaningful sensitivity and specificity," said Erik Larsen, Senior
Vice President of Clinical Development & Customer Success at
Sonde Health. "This study demonstrates the robustness of our tool
across conditions, geographies, and languages, paving the way for
broader respiratory disease monitoring and surveillance efforts
going forward."
The study enrolled 497 participants across four clinical sites
in the United States and India, including patients who were
COVID-19 positive, patients who had other acute illnesses, and
asymptomatic volunteers who did not have an acute illness at the
time of the study.
Dr. Sunit Jariwala, M.D., Professor of Medicine and Director of
Clinical Research and Innovation in the Department of Medicine at
Einstein College of Medicine and Montefiore Health System, served
as principal investigator for the study. "This study highlights the
potential of vocal biomarkers to improve access and outcomes for
diverse and varied populations with respiratory diseases," he said.
"By utilizing a digital tool that is non-invasive and can be easily
scaled and distributed, we can effectively monitor respiratory
health and identify individuals' levels of symptoms and risk. Based
on the promising results from this study, we are working with Sonde
Health to study the RRVB tool for respiratory monitoring in
patients with moderate-to-severe asthma , and we are at the
beginning stages of an Agency for Healthcare Research and Quality
(AHRQ)-funded study to incorporate the RRVB tool into our own
ASTHMAXcel mobile platform."
The RRVB tool was originally developed and tested using a
diverse dataset that included over 3,000 patients with respiratory
conditions, including asthma, COPD, and interstitial lung disease,
as well as healthy individuals. The data was collected from more
than 20 hospitals across India between August 2018 and January 2020
and encompassed multiple languages.
The COVID-19 validation study tested this tool for its ability
to differentiate patients with COVID-19 from healthy individuals
with data collected from September 2020 through April 2021.
About Sonde Health
Sonde Health is a leader in voice-based health monitoring. Sonde
serves top health companies, providers, pharma, and device OEMs
through its vocal biomarker platform. Leveraging a best-in-class
voice data set with over 1.2 million samples from 85,000+
individuals on four continents, Sonde uses advanced audio signal
processing, speech science, and AI/machine learning to sense and
analyze subtle vocal changes due to changes in a person's
physiology to provide key insights into health and well-being.
www.sondehealth.com
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to giving life to new classes of medicine to change the lives of
patients with devastating diseases. The Company has created a broad
and deep pipeline through its experienced research and development
team and its extensive network of scientists, clinicians and
industry leaders that is being advanced both internally and through
its Founded Entities. PureTech's R&D engine has resulted in the
development of 27 therapeutics and therapeutic candidates,
including two ( Plenity (R) and EndeavorRx (R)) that have received
both US FDA clearance and European marketing authorization and a
third ( KarXT ) that is expected to be filed soon for FDA approval.
A number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical
development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation
points.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those statements that relate to the ability of
Sonde's RRVB machine learning model, and Sonde's and PureTech's
future prospects, development plans, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks, uncertainties and other
important factors that could cause actual results, performance and
achievements to differ materially from current expectations,
including, but not limited to, the following: our history of
incurring significant operating losses since our inception; our
need for additional funding to achieve our business goals, which
may not be available and which may force us to delay, limit or
terminate certain of our therapeutic development efforts; our
limited information about and limited control or influence over our
Non-Controlled Founded Entities; the lengthy and expensive process
of preclinical and clinical drug development, which has an
uncertain outcome and potential for substantial delays; potential
difficulties with enrolling patients in clinical trials, which
could delay our clinical development activities; side effects,
adverse events or other safety risks which could be associated with
our therapeutic candidates and delay or halt their clinical
development; our ability to obtain regulatory approval for and
commercialize our therapeutic candidates; our ability to realize
the benefits of our collaborations, licenses and other
arrangements; our ability to maintain and protect our intellectual
property rights; our reliance on third parties, including clinical
research organizations, clinical investigators and manufacturers;
our vulnerability to natural disasters, global economic factors,
geo-political actions and unexpected events; and those additional
important factors described under the caption "Risk Factors" in our
Annual Report on Form 20-F for the year ended December 31, 2022
filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the Company
and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements, we
disclaim any obligation to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media
Nichole Sarkis
+1 774 278 8273
nichole@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAXSAALLDEFA
(END) Dow Jones Newswires
May 23, 2023 09:05 ET (13:05 GMT)
Puretech Health (LSE:PRTC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Puretech Health (LSE:PRTC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024